Paper: Real-World Outcomes with Fedratinib Therapy in Patients Who Discontinued Ruxolitinib for Primary Myelofibrosis
Real-world Outcomes of Fedratinib in Patients with Myelofibrosis who Discontinued Ruxolitinib
Related Articles
Regressing calcifications in the carotid artery: What’s going on? A case series
Read the full article here
Coronary Artery Calcium and cardiovascular risk factors analysis after Radiotherapy for breast cancer
Read the full article here
Recent Nutraceutical Interventions for Hypertension: A Comprehensive Review of Randomized Clinical Evidence
Read the full article here